# Cost Savings from Decentralized Clinical Trials * **Net financial benefit:** In phase II studies, the typical DCT deployment for a clinical trial resulting in a one to three month time savings yields a net benefit that is up to five times greater than the upfront investment required. In phase III studies, a similar time savings yields a net benefit that is up to [14 times greater](https://www.businesswire.com/news/home/20220113005740/en/New-Study-Decentralized-Clinical-Trials-Can-Achieve-Net-Financial-Benefits-of-5X-to-14X-Due-to-Reduced-Trial-Timelines-and-Other-Factors) than the upfront investment required. * **Shorter clinical trial times**: Cycle time reductions associated with DCT deployments had a substantially greater impact on net financial benefits than any other factor. Nearly 85 percent of all clinical trials will experience some sort of delay, with the financial impact of [$600,000 to $8 million](https://www.businesswire.com/news/home/20220113005740/en/New-Study-Decentralized-Clinical-Trials-Can-Achieve-Net-Financial-Benefits-of-5X-to-14X-Due-to-Reduced-Trial-Timelines-and-Other-Factors) per day of delay. Faster trial completion through decentralized methodologies can drive significant cost savings. * **Lower screening failure rates**: Less than 5 percent of the U.S. population participates in clinical research, and up to [50 percent of trials are not completed](https://www.businesswire.com/news/home/20220113005740/en/New-Study-Decentralized-Clinical-Trials-Can-Achieve-Net-Financial-Benefits-of-5X-to-14X-Due-to-Reduced-Trial-Timelines-and-Other-Factors) because of insufficient enrollment. DCTs shift the paradigm to enable greater patient participation, reduced time and travel burden, faster screening, more convenient consent and enrollment, and in some cases, remote delivery of an intervention and the measurement of outcomes. * **Fewer protocol amendments:** Protocol amendments often cause delays and dramatically increase the costs of developing new therapies. The potential for fewer research sites in a DCT leads to fewer institutional review boards and a corresponding reduction in regulatory costs and increased flexibility around protocol changes. * In phase II studies, the typical decentralized clinical trial (DCT) deployment produced a [400%](https://github.com/cure-dao/docs/blob/main/assets/financial-benefits-of-decentralized-trials.pdf) return on investment in terms of trial cost reductions. * In phase III studies, decentralization produced a [1300%](https://github.com/cure-dao/docs/blob/main/assets/financial-benefits-of-decentralized-trials.pdf) return on investment. --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://why.dfda.earth/2-solution/cost-savings-from-decentralized-clinical-trials.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.